JAKAFI’s demand continues to grow in Polycythemia Vera
The therapeutic paradigm for Polycythemia Vera patients has shifted significantly in the last few years. Previously, the Polycythemia Vera treatment landscape was dominated by generic medicines such as aspirin, hydroxyurea, interferons, and phlebotomy until the approval of JAKAFI (ruxolitinib) in the US in 2014, a JAK inhibitor developed by Incyte as a second-line treatment for Polycythemia Vera patients. Another achievement in this space emerged in 2021 when PharmaEssentia’s BESREMi, an interferon, was approved in the United States as a monotherapy in the first-line setting. This content is a walkthrough of ...
